PL3431502T3 - Przeciwciało anty-cMet - Google Patents

Przeciwciało anty-cMet

Info

Publication number: PL3431502T3
Authority: PL; Poland
Prior art keywords: cmet antibody; cmet; antibody
Prior art date: 2008-12-02

Application number

PL18188726T

Other languages

English (en)

Inventor

Liliane Goetsch

Thierry Wurch

Cédric BES

Original Assignee

Pierre Fabre Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-02

Filing date

2009-12-02

Publication date

2020-12-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3431502(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-12-02 Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en

2009-12-02 Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament

2020-12-28 Publication of PL3431502T3 publication Critical patent/PL3431502T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)
Medicinal Preparation (AREA)

PL18188726T 2008-12-02 2009-12-02 Przeciwciało anty-cMet PL3431502T3 (pl)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
PCT/IB2008/055663 WO2010064089A1 (en)	2008-12-02	2008-12-02	Novel anti-cmet antibody
US18450209P	2009-06-05	2009-06-05
EP09771324.2A EP2370468B1 (en)	2008-12-02	2009-12-02	ANTI-cMET ANTIBODY
EP18188726.6A EP3431502B1 (en)	2008-12-02	2009-12-02	Anti-cmet antibody
PCT/EP2009/066201 WO2010069765A1 (en)	2008-12-02	2009-12-02	ANTI-cMET ANTIBODY
EP16192250.5A EP3135691B1 (en)	2008-12-02	2009-12-02	Anti-cmet antibody

Publications (1)

Publication Number	Publication Date
PL3431502T3 true PL3431502T3 (pl)	2020-12-28

Family

ID=41693124

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL16192250T PL3135691T3 (pl)	2008-12-02	2009-12-02	Przeciwciało anty-cMet
PL18188726T PL3431502T3 (pl)	2008-12-02	2009-12-02	Przeciwciało anty-cMet
PL09771324T PL2370468T3 (pl)	2008-12-02	2009-12-02	Przeciwciało anty-cMET

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL16192250T PL3135691T3 (pl)	2008-12-02	2009-12-02	Przeciwciało anty-cMet

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL09771324T PL2370468T3 (pl)	2008-12-02	2009-12-02	Przeciwciało anty-cMET

Country Status (38)

Country	Link
US (4)	US8741290B2 (pl)
EP (4)	EP3757132A1 (pl)
JP (3)	JP5863458B2 (pl)
KR (1)	KR101838299B1 (pl)
CN (2)	CN102227446B (pl)
AR (1)	AR074439A1 (pl)
AU (3)	AU2009328318C1 (pl)
BR (2)	BR122019023930B1 (pl)
CA (1)	CA2743433C (pl)
CL (2)	CL2011001296A1 (pl)
CO (1)	CO6382139A2 (pl)
CR (1)	CR20110324A (pl)
CY (2)	CY1119172T1 (pl)
DK (2)	DK3135691T3 (pl)
EC (1)	ECSP11011127A (pl)
ES (3)	ES2827277T3 (pl)
GE (2)	GEP20135930B (pl)
HR (2)	HRP20171011T8 (pl)
HU (3)	HUE040553T2 (pl)
IL (2)	IL213273A0 (pl)
LT (2)	LT3135691T (pl)
MA (1)	MA32892B1 (pl)
MX (2)	MX2011005677A (pl)
MY (2)	MY192567A (pl)
NZ (1)	NZ593853A (pl)
PE (1)	PE20120343A1 (pl)
PH (1)	PH12015501515A1 (pl)
PL (3)	PL3135691T3 (pl)
PT (3)	PT3135691T (pl)
RS (2)	RS56204B1 (pl)
RU (2)	RU2015127471A (pl)
SA (2)	SA109300720B1 (pl)
SG (2)	SG171851A1 (pl)
SI (3)	SI3135691T1 (pl)
TN (1)	TN2011000216A1 (pl)
TW (2)	TWI459964B (pl)
WO (1)	WO2010069765A1 (pl)
ZA (1)	ZA201105164B (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2014681A1 (en)	2007-07-12	2009-01-14	Pierre Fabre Medicament	Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) *	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody
EP2287197A1 (en) *	2009-08-21	2011-02-23	Pierre Fabre Medicament	Anti-cMET antibody and its use for the detection and the diagnosis of cancer
EP3511342B1 (en)	2010-03-10	2024-01-17	Genmab A/S	Monoclonal antibodies against c-met
KR20140019284A (ko)	2010-09-03	2014-02-14	아카데미아 시니카	항-C-Met 항체 및 이의 이용 방법들
EP2635602B1 (en)	2010-11-03	2016-09-07	Argen-X Nv	Anti c-met antibodies
WO2012158818A2 (en)	2011-05-16	2012-11-22	Fabion Pharmaceuticals, Inc.	Multi-specific fab fusion proteins and methods of use
KR101865223B1 (ko)	2011-10-05	2018-06-08	삼성전자주식회사	항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) *	2011-10-05	2013-04-15	삼성전자주식회사	ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
US9926364B2 (en)	2011-11-03	2018-03-27	Argen-X N.V.	Chimeric human-llama antigens and methods of use
KR101463098B1 (ko)	2011-11-28	2014-11-27	한국생명공학연구원	ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
KR101910601B1 (ko)	2011-12-22	2018-10-23	삼성전자주식회사	면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
WO2013192594A2 (en) *	2012-06-21	2013-12-27	Sorrento Therapeutics Inc.	Antigen binding proteins that bind c-met
EP2708556B1 (en)	2012-09-12	2018-11-07	Samsung Electronics Co., Ltd	Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
CN104837502B (zh)	2012-10-12	2018-08-10	麦迪穆有限责任公司	吡咯并苯并二氮杂卓及其结合物
CA2905181C (en)	2013-03-13	2020-06-02	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
KR102049990B1 (ko) *	2013-03-28	2019-12-03	삼성전자주식회사	c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
EP2992019B1 (en)	2013-04-30	2019-03-06	Agency For Science, Technology And Research	Mab 2 anti-met antibody
US9567641B2 (en) *	2013-07-03	2017-02-14	Samsung Electronics Co., Ltd.	Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en)	2013-11-15	2017-08-01	Samsung Electronics Co., Ltd.	Method of combination therapy using an anti-C-Met antibody
ES2729797T3 (es) *	2013-12-20	2019-11-06	Dev Ct Biotechnology	Anticuerpos específicos de la alfa-enolasa y métodos de uso en terapias contra el cáncer
JP6531166B2 (ja)	2014-09-10	2019-06-12	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	ピロロベンゾジアゼピン及びそのコンジュゲート
CN107613974B (zh)	2015-03-16	2021-01-15	塞尔德克斯医疗公司	抗-met抗体及其使用方法
JP6669882B2 (ja) *	2016-02-05	2020-03-18	ヘリックスミスカンパニーリミテッド	抗−ｃ−ＭＥＴ抗体及びその用途
CN109476756B (zh)	2016-03-15	2022-05-31	埃泰美德(香港)有限公司	一种多特异性Fab融合蛋白及其用途
RS61659B1 (sr) *	2016-05-17	2021-04-29	Abbvie Biotherapeutics Inc	Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
US10457726B2 (en)	2016-06-30	2019-10-29	University Of Connecticut	Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
CN109862919A (zh)	2016-10-11	2019-06-07	免疫医疗有限公司	抗体-药物缀合物联合免疫介导的治疗剂
WO2018088933A1 (en) *	2016-11-14	2018-05-17	Limited Liability Company "Panacela Labs"	Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
TWI782930B (zh)	2016-11-16	2022-11-11	美商再生元醫藥公司	抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018129029A1 (en) *	2017-01-04	2018-07-12	Immunogen, Inc.	Met antibodies and immunoconjugates and uses thereof
CN109771642B (zh)	2017-11-13	2022-09-20	同济大学苏州研究院	c-MET激动型抗体及其用途
GB201803892D0 (en)	2018-03-12	2018-04-25	Ultrahuman Six Ltd	C-met binding agents
CA3098103A1 (en)	2018-05-23	2019-11-28	Adc Therapeutics Sa	Molecular adjuvant
US12378318B2 (en) *	2018-08-08	2025-08-05	Dragonfly Therapeutics, Inc.	Proteins binding NKG2D, CD16 and a tumor-associated antigen
EP3847196A4 (en)	2018-09-07	2023-01-04	ITabMed (HK) Limited	BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN109541221B (zh) *	2018-10-24	2022-03-22	益善生物技术股份有限公司	一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko)	2018-11-14	2022-01-20	주식회사 헬릭스미스	안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
WO2020132810A1 (en)	2018-12-24	2020-07-02	Generon (Shanghai) Corporation Ltd.	Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CN113874392B (zh) *	2019-03-28	2025-10-21	丹尼斯科美国公司	工程化抗体
US11896682B2 (en)	2019-09-16	2024-02-13	Regeneron Pharmaceuticals, Inc.	Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
EP4129335A4 (en)	2020-09-01	2024-04-24	RemeGen Co., Ltd.	ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS
US20230372528A1 (en)	2020-10-16	2023-11-23	University Of Georgia Research Foundation, Inc.	Glycoconjugates
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
CA3214989A1 (en)	2021-04-06	2022-10-13	Abbvie Biotherapeutics Inc.	Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin
CN117157325A (zh) *	2021-04-08	2023-12-01	拜奥迪斯私人有限公司	抗c-met抗体和抗体-药物缀合物
TW202547842A (zh)	2021-04-29	2025-12-16	愛爾蘭商艾伯維製造管理無限公司	抗c-Met抗體藥物結合物
CN117980327A (zh)	2021-11-03	2024-05-03	杭州多禧生物科技有限公司	抗体的特异性偶联
US20230285394A1 (en)	2022-03-11	2023-09-14	Abbvie Biotherapeutics Inc.	Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib
IL324585A (en)	2023-05-23	2026-01-01	Abbvie Mfg Management Unlimited Company	Methods of treatment using anti-c-met antibody drug conjugates
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4424200A (en)	1979-05-14	1984-01-03	Nuc Med Inc.	Method for radiolabeling proteins with technetium-99m
US4479930A (en)	1982-07-26	1984-10-30	Trustees Of The University Of Massachusetts	Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8924581D0 (en)	1989-11-01	1989-12-20	Pa Consulting Services	Bleaching of hair
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5639641A (en) *	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5686292A (en) *	1995-06-02	1997-11-11	Genentech, Inc.	Hepatocyte growth factor receptor antagonist antibodies and uses thereof
WO2002055106A2 (en) *	2001-01-09	2002-07-18	Merck Patent Gmbh	Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
WO2004072117A2 (en) *	2003-02-13	2004-08-26	Pharmacia Corporation	Antibodies to c-met for the treatment of cancers
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
US20050233960A1 (en) *	2003-12-11	2005-10-20	Genentech, Inc.	Methods and compositions for inhibiting c-met dimerization and activation
EP1773885B1 (en)	2004-08-05	2010-04-21	Genentech, Inc.	Humanized anti-cmet antagonists
WO2006116260A2 (en) *	2005-04-26	2006-11-02	Medimmune, Inc.	Modulation of antibody effector function by hinge domain engineering
AU2006270009A1 (en) *	2005-07-18	2007-01-25	Amgen Inc.	Human anti-B7RP1 neutralizing antibodies
WO2007016285A2 (en) *	2005-07-28	2007-02-08	Novartis Ag	M-csf specific monoclonal antibody and uses thereof
EP2004693B1 (en) *	2006-03-30	2012-06-06	Novartis AG	Compositions and methods of use for antibodies of c-met
EP2014681A1 (en) *	2007-07-12	2009-01-14	Pierre Fabre Medicament	Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en)	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody

2009
- 2009-12-01 AR ARP090104624A patent/AR074439A1/es active IP Right Grant
- 2009-12-02 SI SI200931893T patent/SI3135691T1/sl unknown
- 2009-12-02 HU HUE16192250A patent/HUE040553T2/hu unknown
- 2009-12-02 RU RU2015127471A patent/RU2015127471A/ru not_active Application Discontinuation
- 2009-12-02 SI SI200931680T patent/SI2370468T1/sl unknown
- 2009-12-02 PT PT16192250T patent/PT3135691T/pt unknown
- 2009-12-02 PT PT181887266T patent/PT3431502T/pt unknown
- 2009-12-02 TW TW098141151A patent/TWI459964B/zh active
- 2009-12-02 EP EP20187010.2A patent/EP3757132A1/en active Pending
- 2009-12-02 RS RS20170671A patent/RS56204B1/sr unknown
- 2009-12-02 TW TW103130374A patent/TWI523866B/zh active
- 2009-12-02 DK DK16192250.5T patent/DK3135691T3/en active
- 2009-12-02 SG SG2011038817A patent/SG171851A1/en unknown
- 2009-12-02 HR HRP20171011TT patent/HRP20171011T8/hr unknown
- 2009-12-02 KR KR1020117013758A patent/KR101838299B1/ko active Active
- 2009-12-02 GE GEAP200912279A patent/GEP20135930B/en unknown
- 2009-12-02 BR BR122019023930-4A patent/BR122019023930B1/pt active IP Right Grant
- 2009-12-02 WO PCT/EP2009/066201 patent/WO2010069765A1/en not_active Ceased
- 2009-12-02 RU RU2011124751/10A patent/RU2560257C2/ru active
- 2009-12-02 NZ NZ593853A patent/NZ593853A/xx unknown
- 2009-12-02 PL PL16192250T patent/PL3135691T3/pl unknown
- 2009-12-02 JP JP2011539008A patent/JP5863458B2/ja active Active
- 2009-12-02 EP EP09771324.2A patent/EP2370468B1/en active Active
- 2009-12-02 RS RS20181344A patent/RS58018B1/sr unknown
- 2009-12-02 MY MYPI2020006937A patent/MY192567A/en unknown
- 2009-12-02 AU AU2009328318A patent/AU2009328318C1/en active Active
- 2009-12-02 ES ES18188726T patent/ES2827277T3/es active Active
- 2009-12-02 CN CN200980148150.4A patent/CN102227446B/zh active Active
- 2009-12-02 BR BRPI0923231A patent/BRPI0923231B8/pt active IP Right Grant
- 2009-12-02 LT LTEP16192250.5T patent/LT3135691T/lt unknown
- 2009-12-02 CA CA2743433A patent/CA2743433C/en active Active
- 2009-12-02 EP EP18188726.6A patent/EP3431502B1/en active Active
- 2009-12-02 SG SG2013005772A patent/SG187518A1/en unknown
- 2009-12-02 LT LTEP09771324.2T patent/LT2370468T/lt unknown
- 2009-12-02 PE PE2011001117A patent/PE20120343A1/es active IP Right Grant
- 2009-12-02 ES ES09771324.2T patent/ES2629855T3/es active Active
- 2009-12-02 PL PL18188726T patent/PL3431502T3/pl unknown
- 2009-12-02 PL PL09771324T patent/PL2370468T3/pl unknown
- 2009-12-02 DK DK09771324.2T patent/DK2370468T3/en active
- 2009-12-02 SI SI200932092T patent/SI3431502T1/sl unknown
- 2009-12-02 HU HUE18188726A patent/HUE051288T2/hu unknown
- 2009-12-02 PT PT97713242T patent/PT2370468T/pt unknown
- 2009-12-02 US US13/132,211 patent/US8741290B2/en active Active
- 2009-12-02 MX MX2011005677A patent/MX2011005677A/es active IP Right Grant
- 2009-12-02 ES ES16192250T patent/ES2697098T3/es active Active
- 2009-12-02 EP EP16192250.5A patent/EP3135691B1/en active Active
- 2009-12-02 HU HUE09771324A patent/HUE035047T2/en unknown
- 2009-12-02 GE GEAP200912919A patent/GEP20146207B/en unknown
- 2009-12-02 MY MYPI2011002426A patent/MY185200A/en unknown
- 2009-12-02 CN CN201310286587.2A patent/CN103351438B/zh active Active
- 2009-12-05 SA SA109300720A patent/SA109300720B1/ar unknown
- 2009-12-05 SA SA112331005A patent/SA112331005B1/ar unknown
2011
- 2011-05-03 TN TN2011000216A patent/TN2011000216A1/fr unknown
- 2011-05-30 MX MX2015000383A patent/MX341014B/es unknown
- 2011-05-31 IL IL213273A patent/IL213273A0/en active IP Right Grant
- 2011-06-01 CL CL2011001296A patent/CL2011001296A1/es unknown
- 2011-06-10 MA MA33933A patent/MA32892B1/fr unknown
- 2011-06-13 EC EC2011011127A patent/ECSP11011127A/es unknown
- 2011-06-13 CR CR20110324A patent/CR20110324A/es unknown
- 2011-06-14 CO CO11073992A patent/CO6382139A2/es active IP Right Grant
- 2011-07-13 ZA ZA2011/05164A patent/ZA201105164B/en unknown
2012
- 2012-09-14 US US13/619,910 patent/US8729249B2/en active Active
- 2012-09-14 US US13/619,730 patent/US8747850B2/en active Active
- 2012-09-14 US US13/619,920 patent/US8765128B2/en active Active
2014
- 2014-01-24 CL CL2014000181A patent/CL2014000181A1/es unknown
- 2014-03-13 IL IL231525A patent/IL231525B/en active IP Right Grant
2015
- 2015-07-03 PH PH12015501515A patent/PH12015501515A1/en unknown
- 2015-12-15 JP JP2015244007A patent/JP6074018B2/ja active Active
2016
- 2016-02-04 AU AU2016200725A patent/AU2016200725C1/en active Active
2017
- 2017-01-05 JP JP2017000641A patent/JP6309657B2/ja active Active
- 2017-06-09 AU AU2017203929A patent/AU2017203929B2/en active Active
- 2017-07-03 CY CY20171100707T patent/CY1119172T1/el unknown
2018
- 2018-11-09 HR HRP20181868TT patent/HRP20181868T1/hr unknown
- 2018-11-09 CY CY181101191T patent/CY1121025T1/el unknown

Also Published As

Publication number	Publication date
ECSP11011127A (es)	2011-07-29
AU2009328318A1 (en)	2011-07-28
US8729249B2 (en)	2014-05-20
JP2016117721A (ja)	2016-06-30
CA2743433A1 (en)	2010-06-24
EP2370468B1 (en)	2017-04-05
MA32892B1 (fr)	2011-12-01
BRPI0923231B1 (pt)	2020-04-28
PE20120343A1 (es)	2012-04-16
US8741290B2 (en)	2014-06-03
HRP20181868T1 (hr)	2019-01-11
RU2015127471A (ru)	2018-12-21
AU2016200725C1 (en)	2017-10-19
HRP20171011T1 (hr)	2017-09-22
PT3431502T (pt)	2020-10-29
MX2011005677A (es)	2011-06-30
EP3135691A1 (en)	2017-03-01
WO2010069765A1 (en)	2010-06-24
MX341014B (es)	2016-08-03
AU2017203929A1 (en)	2017-07-06
EP3135691B1 (en)	2018-08-15
HK1162536A1 (zh)	2012-08-31
TW201446805A (zh)	2014-12-16
ES2697098T3 (es)	2019-01-22
RU2560257C2 (ru)	2015-08-20
NZ593853A (en)	2013-03-28
HUE040553T2 (hu)	2019-03-28
RS58018B1 (sr)	2019-02-28
MY192567A (en)	2022-08-29
CO6382139A2 (es)	2012-02-15
US20130109841A1 (en)	2013-05-02
HUE035047T2 (en)	2018-05-02
CN102227446B (zh)	2015-10-21
PL2370468T3 (pl)	2017-09-29
DK3135691T3 (en)	2018-11-19
CN102227446A (zh)	2011-10-26
SA109300720B1 (ar)	2013-05-25
TWI523866B (zh)	2016-03-01
JP2017099392A (ja)	2017-06-08
EP2370468A1 (en)	2011-10-05
BRPI0923231A2 (pt)	2016-01-26
SI3431502T1 (sl)	2021-01-29
GEP20146207B (en)	2014-12-10
MY185200A (en)	2021-04-30
AU2009328318C1 (en)	2017-11-02
EP3431502B1 (en)	2020-07-22
AR074439A1 (es)	2011-01-19
DK2370468T3 (en)	2017-06-19
PT2370468T (pt)	2017-07-13
HUE051288T2 (hu)	2021-03-01
CA2743433C (en)	2019-06-11
AU2017203929B2 (en)	2019-03-28
TW201023892A (en)	2010-07-01
RU2011124751A (ru)	2013-01-10
RS56204B1 (sr)	2017-11-30
SI3135691T1 (sl)	2018-12-31
PT3135691T (pt)	2018-11-27
TN2011000216A1 (en)	2012-12-17
ZA201105164B (en)	2012-03-28
BR122019023930B1 (pt)	2021-05-04
CY1121025T1 (el)	2019-12-11
ES2629855T3 (es)	2017-08-16
SG171851A1 (en)	2011-07-28
LT2370468T (lt)	2017-07-10
AU2009328318B2 (en)	2015-11-05
JP5863458B2 (ja)	2016-02-16
BRPI0923231B8 (pt)	2021-05-25
CR20110324A (es)	2011-07-28
CN103351438B (zh)	2016-04-20
CL2011001296A1 (es)	2011-08-26
US20110239316A1 (en)	2011-09-29
ES2827277T3 (es)	2021-05-20
JP6074018B2 (ja)	2017-02-01
EP3757132A1 (en)	2020-12-30
PL3135691T3 (pl)	2019-02-28
IL231525A0 (en)	2014-04-30
KR20110097839A (ko)	2011-08-31
PH12015501515A1 (en)	2015-12-14
AU2016200725A1 (en)	2016-02-25
LT3135691T (lt)	2018-11-12
TWI459964B (zh)	2014-11-11
GEP20135930B (en)	2013-10-10
SA112331005B1 (ar)	2015-09-13
HK1190414A1 (zh)	2014-07-04
CY1119172T1 (el)	2018-02-14
HRP20171011T8 (hr)	2019-01-25
IL213273A0 (en)	2011-07-31
JP2012510280A (ja)	2012-05-10
US20130109840A1 (en)	2013-05-02
JP6309657B2 (ja)	2018-04-11
EP3431502A1 (en)	2019-01-23
CN103351438A (zh)	2013-10-16
AU2016200725B2 (en)	2017-05-25
IL231525B (en)	2019-07-31
KR101838299B1 (ko)	2018-03-14
US8747850B2 (en)	2014-06-10
SG187518A1 (en)	2013-02-28
US8765128B2 (en)	2014-07-01
SI2370468T1 (sl)	2017-08-31
US20130109844A1 (en)	2013-05-02
CL2014000181A1 (es)	2014-07-25

Publication	Publication Date	Title
HRP20181868T1 (hr)	2019-01-11	Anti-cmet antitijelo
IL276622A (en)	2020-09-30	Antibody formulation
ZA201102119B (en)	2011-12-28	Improved antibody libraies
ZA201008024B (en)	2012-04-25	Anti-flt3 antibodies
GB0821100D0 (en)	2008-12-24	Antibodies
EP2077859A4 (en)	2010-11-24	ANTIBODY FORMULATION
PL2146745T3 (pl)	2015-11-30	Pięcioswoiste przeciwciało
EP2138576A4 (en)	2011-02-23	ANTI-CLAUDIN-4 ANTIBODY
ZA201101343B (en)	2011-11-30	Novel antibody formulation
ZA201006099B (en)	2012-01-25	Anti-tyrp1 antibodies
IL205073A0 (en)	2010-11-30	Anti-bst2 antibody
ZA201007976B (en)	2012-02-29	Anti-pirb antibodies
GB0818356D0 (en)	2008-11-12	Antibodies
GB0911770D0 (en)	2009-08-19	Antibody
GB0817622D0 (en)	2008-11-05	Antibody
GB0817621D0 (en)	2008-11-05	Antibody
GB0806230D0 (en)	2008-05-14	Antibodies
GB0823562D0 (en)	2009-01-28	Antibodies
GB0819113D0 (en)	2008-11-26	An antibody